TL;DR
- •Sublingual ketamine (oral lozenges dissolved under the tongue) and IV ketamine (intravenous infusion in a clinic) both deliver the same active medication via different absorption routes.
- •IV bioavailability is ~100% with peak concentration in minutes; sublingual is ~25-30% with peak concentration in 30-45 minutes. IV produces a more intense dissociative experience; sublingual is gentler.
- •IV infusions are typically 40-minute sessions in a clinic with monitoring; sublingual dosing happens at home under physician supervision with prep and integration.
- •Cost: IV ketamine is typically $400-800 per session ($2400-4800 for a 6-session induction). Tovani's sublingual is $349/month including unlimited maintenance sessions.
- •Both produce comparable antidepressant outcomes per available evidence; choice usually comes down to cost, access, and patient preference for the experience.
- •For most ambulatory patients, sublingual at-home ketamine is the practical default. IV is preferred when faster onset, more controlled dissociation, or specific pain-syndrome indications matter most.
Side by side
Sublingual ketamine
Oral lozenge formulation (off-label for depression)
What it treats
Treatment-resistant depression, Anxiety, PTSD, Chronic pain (off-label)
Mechanism
Ketamine lozenge dissolved under the tongue. Absorbs through oral mucosa, bypassing first-pass liver metabolism. ~25-30% bioavailability with peak plasma levels at 30-45 minutes. Produces NMDA-receptor antagonism and antidepressant cascade comparable to other routes.
Strengths
- •At-home administration — no clinic travel
- •Lower cost ($349/month at Tovani vs $2400+ per induction course IV)
- •Gentler dissociative experience for most patients
- •Same physician relationship via telehealth
Limitations
- •Lower bioavailability requires higher dose to match IV effect
- •Slower onset (30-45 min vs minutes for IV)
- •Bitter taste; some patients struggle with the lozenge experience
- •Requires good adherence — missed integration impacts outcomes
IV ketamine
Intravenous infusion (off-label for depression)
What it treats
Treatment-resistant depression, Treatment-resistant anxiety, PTSD, CRPS / chronic pain syndromes
Mechanism
Ketamine delivered intravenously over 40 minutes in a controlled clinic setting. 100% bioavailability with peak plasma levels within minutes. NMDA-receptor antagonism with the most controlled dose-response.
Strengths
- •Highest bioavailability — predictable, controlled dosing
- •Fastest onset of dissociation and antidepressant effect
- •Most evidence base in published trials (most studies used IV)
- •Specific advantage for chronic pain syndromes (CRPS, neuropathic pain)
Limitations
- •In-clinic only — appointment, travel, and 2-3 hour total time burden
- •Higher per-session cost ($400-800)
- •More intense dissociative experience can be uncomfortable for some patients
- •IV access required — minor but real barrier for some patients
Which one for your situation?
If:
Standard treatment-resistant depression with no specific pain or rapid-onset urgency
Verdict:
Sublingual — equivalent outcomes, lower cost, at-home convenience
If:
Chronic pain syndrome (CRPS, fibromyalgia) is the primary indication
Verdict:
IV — strongest evidence base for pain-specific indications
If:
Severe acute depression or suicidal ideation requiring fastest possible onset
Verdict:
IV — minutes-to-onset can matter clinically in acute scenarios
If:
Mobility limitations or rural location limiting clinic access
Verdict:
Sublingual at-home
If:
Cost-sensitive patient without insurance coverage for clinic IV
Verdict:
Sublingual — much lower total cost
If:
Want maximum controlled clinical environment for first ketamine experience
Verdict:
IV — in-clinic monitoring provides immediate clinical support
Where ketamine fits
Tovani delivers sublingual ketamine via telehealth in Florida and New Jersey — the practical default for most ambulatory patients with treatment-resistant depression, anxiety, or PTSD. IV-ketamine clinics exist regionally and are the right call for specific clinical scenarios (chronic pain, acute crisis, patient preference for in-clinic).
IV ketamine produces dissociation within minutes; sublingual within 30-45 minutes. Both produce measurable mood response within hours of the first session — the gap closes once the medication is fully absorbed.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is IV ketamine stronger than sublingual?
Per-milligram, yes — IV has ~100% bioavailability vs ~25-30% sublingual. But sublingual dosing accounts for this; the goal isn't the same milligram dose, it's comparable therapeutic effect. Outcome studies suggest comparable antidepressant response between the two routes when each is dosed appropriately.
Will sublingual ketamine work for me if IV worked?
Usually yes. Patients transitioning from IV induction to sublingual maintenance is a common pattern. The mechanism is identical (NMDA antagonism); the absorption route differs. Some patients do prefer the IV experience and stay with it, but most can maintain response with sublingual at home.
Why is IV ketamine so much more expensive?
IV requires a licensed clinic with monitoring staff, IV equipment, and physician supervision for the full session — overhead costs are much higher than at-home telehealth. The medication itself is generic and cheap; the clinic infrastructure drives the cost differential.
Is the dissociation different?
IV produces faster, more intense, and shorter-duration dissociation (peaks within ~10-15 minutes, resolves within 90 minutes). Sublingual produces a gentler, longer-onset, longer-lasting dissociation (peaks at 60-90 minutes, resolves over 2-3 hours). Some patients prefer the controlled clinical setting for the more intense IV experience; others prefer the gentler sublingual at home.
Can I switch between routes?
Yes — IV induction followed by sublingual maintenance is one common pattern. Or starting sublingual and switching to IV if maintenance isn't holding. Your physician helps you figure out the right pattern based on your response and life situation.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. IV ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo. The reference trial that established the antidepressant effect; subsequent sublingual studies show comparable outcomes. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — addresses routes of administration and clinical-context guidance for IV vs sublingual vs intranasal. PMID 28249076